Healthcare Services

Hereditary Angioedema Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Hereditary Angioedema Market During The Forecast Period 2026–2030?

The hereditary angioedema market has shown significant growth in recent years. It is projected to expand from $2.81 billion in 2025 to $3.04 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. The growth observed in prior periods can be attributed to factors such as increasing clinical awareness of rare genetic disorders, the availability of plasma-derived c1 esterase inhibitors, the expansion of specialty treatment centers, improvements in diagnostic accuracy for hae, and the rise of patient advocacy initiatives.

The hereditary angioedema market is anticipated to undergo substantial growth in the forthcoming years. It is projected to expand to $4.15 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This expansion during the forecast period is primarily driven by the increasing availability of innovative oral and subcutaneous therapies, heightened investment in developing treatments for rare diseases, a growing embrace of personalized medicine strategies, the development of genetic screening programs, and improved long-term disease management methods. Furthermore, key trends influencing this period include the wider adoption of targeted bradykinin therapies, an increase in the utilization of prophylactic treatment regimens, a stronger focus on early genetic diagnosis, the broadening of home-based self-administration treatments, and more refined patient-centric care approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

What Drivers Are Expected To Influence The Hereditary Angioedema Market During The Forecast Period?

The hereditary angioedema market is anticipated to experience growth driven by the rising occurrence of rare diseases. Rare diseases, also referred to as orphan diseases, are medical conditions that affect only a small segment of the population. This increasing prevalence of rare diseases stems from various factors, including advancements in medical research, shifts in population demographics, and environmental influences. Hereditary angioedema (HAE) stands out as a significant rare disease, emphasizing the critical need for specialized treatments and public awareness due to its life-threatening swelling episodes. Its uncommon nature and genetic origins make early diagnosis and targeted therapies vital for effective management and enhanced patient outcomes. For instance, The American Cancer Society, a US-based professional organization, projected in January 2025 that an estimated 59,660 new cases of oral cavity and oropharyngeal cancer would be diagnosed in 2025, with approximately 12,770 people expected to die from these cancers. Therefore, the expanding prevalence of rare diseases is a key factor propelling the growth of the hereditary angioedema market.

What Market Segments Are Evaluated Within The Hereditary Angioedema Market?

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

How Are Trends Impacting The Hereditary Angioedema Market?

Major companies within the hereditary angioedema market are developing advanced products, such as oral plasma kallikrein inhibitors, to offer more convenient and effective on-demand treatment options for patients. Oral plasma kallikrein inhibitors are medications that work by blocking plasma kallikrein to prevent excessive bradykinin production, primarily utilized for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat. This experimental oral plasma kallikrein inhibitor is intended for the immediate treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat offers a new therapeutic approach by targeting and inhibiting plasma kallikrein activity. The NDA’s acceptance marks a significant milestone towards its potential approval and commercialization.

Who Are The Top Market Participants Influencing The Hereditary Angioedema Market?

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

Read the full hereditary angioedema market report here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Which Region Is Forecast To Lead The Hereditary Angioedema Market In Terms Of Market Size?

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hereditary Angioedema Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Market 2026, By The Business Research Company

Angina Global Market Report

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Angina Pectoris Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Biopsy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795